These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 21671864)

  • 1. Anticancer prodrugs: an overview of major strategies and recent developments.
    Arpicco S; Dosio F; Stella B; Cattel L
    Curr Top Med Chem; 2011; 11(18):2346-81. PubMed ID: 21671864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current prodrug design for drug discovery.
    Hsieh PW; Hung CF; Fang JY
    Curr Pharm Des; 2009; 15(19):2236-50. PubMed ID: 19601825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
    El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
    J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug strategy for cancer cell-specific targeting: A recent overview.
    Zhang X; Li X; You Q; Zhang X
    Eur J Med Chem; 2017 Oct; 139():542-563. PubMed ID: 28837920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.
    van Rijt SH; Sadler PJ
    Drug Discov Today; 2009 Dec; 14(23-24):1089-97. PubMed ID: 19782150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.
    Akinboye ES; Rosen MD; Bakare O; Denmeade SR
    Bioorg Med Chem; 2017 Dec; 25(24):6707-6717. PubMed ID: 29153549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of anticancer prodrugs for reductive activation.
    Chen Y; Hu L
    Med Res Rev; 2009 Jan; 29(1):29-64. PubMed ID: 18688784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity.
    Wang Y; Xin D; Liu K; Zhu M; Xiang J
    Bioconjug Chem; 2009 Dec; 20(12):2214-21. PubMed ID: 19950889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
    Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
    Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
    Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
    Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological studies of the thiols-triggered anticancer prodrug for a more effective cancer therapy.
    Xu Y; Chen J; Li Y; Peng S; Gu X; Sun M; Gao K; Fang J
    Org Biomol Chem; 2015 Mar; 13(9):2634-9. PubMed ID: 25581090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
    Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
    J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies on the development of small molecule anticancer drugs for targeted therapy.
    Lu YH; Gao XQ; Wu M; Zhang-Negrerie D; Gao Q
    Mini Rev Med Chem; 2011 Jun; 11(7):611-24. PubMed ID: 21699492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of 2'-carbamate-linked and 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin.
    de Groot FM; van Berkom LW; Scheeren HW
    J Med Chem; 2000 Aug; 43(16):3093-102. PubMed ID: 10956217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release.
    de Groot FM; Loos WJ; Koekkoek R; van Berkom LW; Busscher GF; Seelen AE; Albrecht C; de Bruijn P; Scheeren HW
    J Org Chem; 2001 Dec; 66(26):8815-30. PubMed ID: 11749612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
    Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
    Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel analogues of CC-1065 and the duocarmycins for the use in targeted tumour therapies.
    Tietze LF; Krewer B
    Anticancer Agents Med Chem; 2009 Mar; 9(3):304-25. PubMed ID: 19275523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of novel 2',3'-didehydro-2',3'-dideoxyinosine phosphoramidate prodrugs and evaluation of their anticancer activity.
    Borek W; Lewandowska M; Kleczewska N; Ruszkowski P; Kacprzak K; Celewicz L
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(8):507-18. PubMed ID: 25009986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assembling nanowires of an amphiphilic camptothecin prodrug derived from homologous derivative conjugation.
    He D; Zhang W; Deng H; Huo S; Wang YF; Gong N; Deng L; Liang XJ; Dong A
    Chem Commun (Camb); 2016 Dec; 52(98):14145-14148. PubMed ID: 27869268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.